Max Lamb

Max Lamb has a diverse range of work experience in various roles and industries. Starting in 2011, they worked as a Research Co-op at Ceramatec, Inc., where they designed and developed ion conducting membranes. In 2012, they were an Engineering & Business Strategy Intern at Adamant Technologies, focusing on breath-based diagnostics using nanotechnology sensors. Max then became a Research Associate at Tsourkas Lab, where they worked on cellular and molecular imaging projects. In 2013, Max joined ClearView Healthcare Partners as an Analyst, conducting market analysis and due diligence on emerging stem cell therapies. In 2014, they co-founded Drop Diagnostics and served as the COO, responsible for product strategy, development, and engineering. In 2015, they became a Business Strategy Analyst/Sales Support Manager at Transcriptic. Most recently, Max was Head of Partnerships at Qualia Labs, Inc., a real estate closing platform.

Max Lamb's education history includes attending the University of Pennsylvania, where they pursued the M&T Program and obtained a BS in Engineering with a focus on Bioengineering. Additionally, they also studied at The Wharton School as part of the M&T Program, earning a second BS in Economics with a specialization in Operations and Information Management. The specific years of enrollment in these institutions are unknown.